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Advances in immunisation, improvements in socioeconomic status 
and effective HIV prevention and treatment strategies have reduced 
the population burden of childhood pneumonia and severe disease. [1] 
However, pneumonia remains the major single cause of death in 
children outside the neonatal period, causing approximately around 
1 million deaths annually, or 15% of an estimated 6.3 million deaths 
in children aged <5 years.[2,3] This burden is disproportionately 
high in low- and middle-income countries (LMICs) and in Africa, 
where almost 50% of deaths in children aged <5 years occur, despite 
African children comprising only 25% of live births globally.[3,4] The 
incidence and severity of pneumonia are highest in the first year of 
life, especially in the first 6 months.[2,5]
New conjugate vaccines against Haemophilus influenzae type b 
(Hib) and Streptococcus pneumoniae (PCV) can substantially reduce 
the burden of childhood pneumonia in vaccinated children. Data 
from six studies of the effectiveness of Hib conjugate vaccine in 
LMICs reported reductions of 18% in radiological pneumonia, 6% in 
severe pneumonia and 7% in pneumonia-associated mortality.[6] The 
impact of PCV in reducing pneumonia hospitalisation, mortality, 
bacteraemic disease and clinical disease in children has been reported 
in several studies.[7-11] PCV immunisation of children has also led to a 
decline in hospitalisation and death due to pneumonia in adults as a 
result of indirect protection through reduction in circulating vaccine-
type pneumococcal serotypes.[7]
Defining pneumonia epidemiology and aetiology in the context 
of strong immunisation programmes is an ongoing priority for child 
health. South Africa (SA) was the first African country to implement 
PCV immunisation in the national immunisation programme; 
7-valent PCV was introduced for infants at 6 and 10 weeks and 
9 months in 2009 and replaced with 13-valent PCV (PCV13) in 
2011. In the context of relatively strong immunisation and primary 
healthcare programmes, it is important to understand the changing 
epidemiology and aetiology of childhood pneumonia.
The Drakenstein Child Health Study is an SA birth cohort study of 
1 000 mother-child pairs that investigates the epidemiology, aetio logy, 
risk factors and long-term outcome of childhood pneumonia and 
determinants of child health.[12] This study takes place at two primary 
healthcare clinics and one hospital in the Drakenstein subdistrict in 
Paarl, a periurban area outside Cape Town. Women enrolled during 
pregnancy are followed through childbirth, and mother-child pairs are 
followed until children are at least 5 years of age. Children receive pri-
mary healthcare and immunisation at clinics. Continuous pneumonia 
surveillance is undertaken.[13] Although the prevalence of HIV infec-
tion in pregnant women in the cohort was around 25%, only 2 children 
were HIV-infected, a reflection of the strong mother-to-child HIV-
prevention programme. To assess pneumonia aetiology, a nested case-
control study was done and respiratory specimens (nasopharyngeal 
swabs and induced sputum) were tested using a multiplex polymerase 
chain reaction to identify up to 33 potential respiratory organisms.[14]
We found that pneumonia remains a major cause of illness (inci-
dence 0.27 episodes per child year) and hospitalisation, particularly 
in the first 6 months of life, despite excellent immunisation coverage 
including PCV13.[14] Several viruses, most strikingly respiratory 
syncytical virus (RSV, the most frequently detected pathogen), were 
strongly associated with pneumonia.[14] Bordetella pertussis was 
strongly associated with pneumonia, but occurred in a small number 
of children; H. influenzae (other than type b) was less strongly 
associated with pneumonia, but was common. Multiple potential 
pathogens were identified at each pneumonia episode, adding 
to evidence that childhood pneumonia may be due to infection 
with multiple organisms, particularly in the case of severe disease. 
Induced sputum provided an increased yield for potential pathogens 
compared with nasopharyngeal specimens, notably for B. pertussis 
and several viruses, suggesting that induced sputum can be used to 
improve diagnostic strategies even in very young infants.[14]
The high burden of childhood pneumonia may partly reflect 
high exposure to potential pathogens and to risk factors that may 
make a child vulnerable to pneumonia. Smoke exposure, lack of 
breastfeeding, prematurity or low birth weight, low socioeconomic 
status, crowded living conditions, or HIV infection or exposure are 
important risk factors for childhood pneumonia that were common 
in this setting and in LMIC settings generally.[2,4] Despite the high 
incidence of pneumonia and of severe disease, there was a low case 
fatality rate, attesting to good access to care and a strong primary 
healthcare programme including use of case management guidelines, 
antibiotics, oxygen, timely referral and access to hospital.[14]
With increasing uptake of PCV in LMICs, the proportion of lower 
respiratory tract infections (LRTIs) due to viruses, particularly RSV, 
may be expected to increase.[15,16] RSV was the commonest identifiable 
organism, and was associated with severe disease but not with 
mortality. This is consistent with global and African data preceding 
PCV that reported RSV to be the commonest pathogen in children 
with LRTI.[17] Globally RSV was estimated to cause approximately 34 
million episodes of acute lower respiratory tract infections (ALRIs) in 
children aged <5 years, or 22% of all ALRIs; 10% of episodes resulted 
in severe illness and hospitalisation, and 99% of deaths occurred in 
LMICs. Further studies in African children preceding the availability 
of PCV,[18,19] and several recent case-control studies in children well 
vaccinated with PCV13, mostly from high-income countries, have 
reported RSV to be a predominant pathogen in children hospitalised 
with pneumonia.[20,21] Consistent with other studies, RSV occurred in 
young infants with the peak incidence under 6 months.[22] Maternal 
immunisation against RSV during late pregnancy may therefore be 
an attractive novel strategy to prevent disease in young infants.[23] In 
addition, B. pertussis occurred in young infants, and mostly before 
completion of the primary series of three immunisations; in turn, 
immunisation of pregnant women with B. pertussis may also be an 
effective strategy to prevent this burden.[24]
As health systems are strengthened, it is crucial to consider the 
impact of childhood pneumonia beyond acute disease in childhood or 
mortality. This is especially relevant as health systems are challenged 
to address the Sustainable Development Goals for 2030. Chronic 
sequelae from early childhood pneumonia such as bronchiectasis 
are increasingly recognised; one review reported chronic sequelae 
following severe pneumonia to occur in ~15% of children.[25] Early 
childhood pneumonia has increasingly been associated with the 
development of chronic non-communicable respiratory diseases into 
childhood and adulthood, such as asthma or chronic obstructive 
airways disease (COPD),[26] of which SA has one of the highest global 
prevalences. Accumulating evidence from several cohort studies 
has shown that lung health is established early in life and that lung 
function follows a set trajectory into adulthood, implying that the 
roots of adult lung disease such as COPD lie in early exposures 
including childhood pneumonia.[27]
For many African countries or LMICs, challenges remain in imple-
menting available effective, preventive and management strategies 
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for childhood pneumonia.[28] However, the Drakenstein Child Health 
Study shows that even in LMIC settings with strong health pro-
grammes, pneumonia remains a major concern for child health. The 
strengthening and implementation of available effective preventive 
and management interventions, such as available immunisations and 
use of case management, have the potential to substantially reduce 
pneumonia burden and under-5 mortality. [6] Strategies to reduce 
risk factors, such as optimising nutrition, promoting breastfeeding, 
preventing HIV transmission through mother-to-child prevention 
programmes and reducing exposure to biomass or cigarette smoke, 
must be strengthened, particularly in Africa. However, our findings 
show that despite good application of these in this area and the low 
prevalence of HIV in children, there is a large residual burden of 
pneumonia, for which novel strategies are required.
While attention to reducing risk factors and strengthening health 
systems to deliver effective preventive and management strategies are 
a priority in LMICs, novel strategies are needed to reduce pneumonia 
incidence, especially looking beyond pneumonia mortality to the 
considerable associated morbidity and development of chronic 
disease. This is a key lesson from the Drakenstein Child Health 
Study, where despite good primary healthcare, high coverage with 
vaccines contained in the SA national immunisation programme, 
very low prevalence of HIV infection in children and good access 
to care, pneumonia remains a major cause of childhood illness.[14] 
Given the considerable burden of LRTI due to RSV and the young 
age of infants most vulnerable to disease and to developing severe 
LRTI, the development of several new RSV vaccine candidates is a 
promising development.[23] A novel strategy to immunise pregnant 
women in the third trimester of pregnancy to protect against RSV 
disease in their infants in the first few months of life has recently been 
developed.[23] This will probably need to be coupled with additional 
vaccination of infants to provide extended protection until children 
are 2 years of age. The challenge for African and other LMICs will 
be to ensure that such new strategies are 
accessible and affordable, if effective.
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